Rare diseases are complex, but the need is urgent. Alexion’s Eunice Alvazzi discusses the shared responsibility in achieving access to innovation in rare diseases
Patients, healthcare professionals, payers, and other stakeholders can have vastly different views on the value of a particular product, often resulting in a struggle between prioritising a
The NHS needs to find a way to put privacy first to build trust with the public around its innovation plans, explains Nigel Jones, co-founder of the Privacy Compliance Hub.
Across the European Union approximately 300,000 patients with chronic conditions, such as haemophilia and severe immune-deficiency, depend on plasma-derived medicines, which can only be man
Modern medicine moves ever more to precision, personalised medicine, and precision dosing is critical in a world that recognises biological individuality – especially when it comes to paedi